https://pubmed.ncbi.nlm.nih.gov/39618087/ Autoimmune liver disease

J Pediatr Gastroenterol Nutr. 2024 Dec 1.
doi: 10.1002/jpn3.12424. Online ahead of print.

Current practice in the management of paediatric autoimmune liver disease in Europe

Mara Cananzi 1, Marianne Hørby Jørgensen 2, Gustav Buescher 3, Ruth De Bruyne 4, Marianne Samyn 5; ESPGHAN Hepatology Interest Group and of the ERN RARE‐LIVER Autoimmune Hepatitis Working Group
Affiliations expand
PMID: 39618087

DOI: 10.1002/jpn3.12424
Abstract

Objective: Paediatric autoimmune liver disease (pAILD) is a rare condition with serious health implications. Notwithstanding treatment advancements, areas of uncertainty and knowledge gaps still exist. We here investigated the real-life approach to pAILD management in Europe.

Methods: A survey was distributed to members of the RARE-LIVER ERN and the ESPGHAN Hepatology Interest Group. Information was gathered regarding clinical activity, medications used, and access to paediatric drug formulations at each site.

Results: Thirty-six centres from 22 European countries responded to the survey. The majority are exclusively paediatric units (86%). Among participants, 80% follow <50 children with pAILD, of which 25%-50% are <10 years old in 44% of centres. All centres use predniso(lo)ne as first-line therapy, alone (15/36) or with azathioprine (21/36). Azathioprine and mycophenolate are the preferred second-line options in centres using first-line steroid monotherapy (11/15) or combined steroid-azathioprine (19/21), respectively. Tacrolimus is used as third-line agent in 15/36 centres. Proactive measurement of drug metabolites and target levels vary widely among centres. Paediatric predniso(lo)ne formulations are commercially available in 7/22 European countries, azathioprine in 3, mycophenolate in 14, tacrolimus in 15 and ursodeoxycholic acid in 14. When paediatric formulations are unavailable, children are treated with magisterial preparations or 'solid' formulations (crushed or intact).

Conclusions: Treatment of pAILD in Europe varies widely in terms of medications used and treatment monitoring. Availability of paediatric drug formulations across Europe is limited. Collaborative initiatives are needed to define evidence-based strategies for management of pAILD and to promote an equal, age-appropriate treatment for affected children.